gip glp 1 agonists The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review Dual and Triple Gut Peptide

Obesity and vitamin D deficiency: a systematic review and meta-analysis

As of March 2025, 11 states cover GLP-1s for weight loss under their state employee health plan, nine states provide coverage under their state Medicaid program, and five states provide coverage under both programs

There is limited peer-reviewed evidence specifically studying GLP-1 microdosing for weight management

Both medications belong to a class called incretin mimetics, but tirzepatide engages a second hormone pathway that semaglutide does not

Yes, persistent or worsening fatigue despite GLP-1 treatment warrants medical review to investigate other potential causes such as anaemia, thyroid disorders, sleep apnoea, depression, or medication side effects

There is also the broader context of platform ecosystems, where integration, fairness audits, and promotions influence perception